• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    2/14/24 4:30:59 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    SC 13G/A 1 ef20021715_sc13ga.htm SC 13G/A
    United States
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     


    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 6)*
     


    BeyondSpring Inc.
    (Name of Issuer)
     
    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
     
    G10830100
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☒
    Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G10830100
    SCHEDULE 13G
    Page 2 of 12
    1
    NAMES OF REPORTING PERSONS
     
     
    Ever Regal Group Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    1,431,686
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    1,431,686
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,431,686
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.67% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,015,476 ordinary shares, par value $0.0001 per share (“Ordinary Shares”) of BeyondSpring Inc. (the “Issuer”) outstanding as of June 30, 2023, as reported in the Issuer’s latest interim report on Form 6-K.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 3 of 12
    1
    NAMES OF REPORTING PERSONS
     
     
    Fairy Eagle Investments Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    175,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    175,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    175,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.45% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,015,476 Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s latest interim report on Form 6-K.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 4 of 12
    1
    NAMES OF REPORTING PERSONS
     
     
    Rosy Time Holdings Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    100,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    100,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    100,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.26% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,015,476 Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s latest interim report on Form 6-K.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 5 of 12
    1
    NAMES OF REPORTING PERSONS
     
     
    Lan Huang
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    10,210,523
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    2,875,523
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,210,523(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    26.17% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

     
    (1)
    Consists of (i) 1,431,686 Ordinary Shares directly held by Ever Regal Group Limited; (ii) 175,000 Ordinary Shares directly held by Fairy Eagle Investments Limited; (iii) 100,000 Ordinary Shares directly held by Rosy Time Holdings Limited, (iv) 73,837 Ordinary Shares directly held by the Lan Huang 2021 Grantor Retained Annuity Trust, (v) 450,000 Ordinary Shares directly held by the Lan Huang 2022 Grantor Retained Annuity Trust, (vi) 277,963 Ordinary Shares owned directly by Dr. Lan Huang; (vii) 137,037 Ordinary Shares owned directly by her spouse, Mr. Linqing Jia; (viii) 230,000 Ordinary Shares held by the Sincere Efforts Foundation Inc., a charitable foundation of which Dr. Huang serves on the board; (ix) 1,800,000 Ordinary Shares directly held by three irrevocable trusts for the benefit of Dr. Huang’s children, over which Dr. Huang has been granted proxy to vote; and (x) 5,535,000 Ordinary Shares directly held by certain unaffiliated third-parties, over which Mr. Jia has been granted proxy to vote.

     
    (2)
    Based on 39,015,476 Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s latest interim report on Form 6-K.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 6 of 12
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Linqing Jia
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    10,210,523
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    2,875,523
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,210,523(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    26.17% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

     
    (1)
    Consists of (i) 1,431,686 Ordinary Shares directly held by Ever Regal Group Limited; (ii) 175,000 Ordinary Shares directly held by Fairy Eagle Investments Limited; (iii) 100,000 Ordinary Shares directly held by Rosy Time Holdings Limited, (iv) 73,837 Ordinary Shares directly held by the Lan Huang 2021 Grantor Retained Annuity Trust, (v) 450,000 Ordinary Shares directly held by the Lan Huang 2022 Grantor Retained Annuity Trust, (vi) 137,037 Ordinary Shares owned directly by Mr. Jia; (vii) 277,963 Ordinary Shares owned directly by his spouse, Dr. Huang; (viii) 230,000 Ordinary Shares held by the Sincere Efforts Foundation Inc., a charitable foundation of which Dr. Huang serves on the board; (ix) 1,800,000 Ordinary Shares directly held by three irrevocable trusts for the benefit of Dr. Huang’s children, over which Dr. Huang has been granted proxy to vote; and (x) 5,535,000 Ordinary Shares directly held by certain unaffiliated third-parties, over which Mr. Jia has been granted proxy to vote.

     
    (2)
    Based on 39,015,476 Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s latest interim report on Form 6-K.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 7 of 12

    Item 1(a)
    Name of Issuer:
     
    BeyondSpring Inc. (the “Issuer”)
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
     
    100 Campus Drive, West Side, 4th Floor, Suite 410
    Florham Park, New Jersey 07932
     
    Item 2(a)-(c)
    Name of Persons Filing; Address of Principal Business Office; and Citizenship
     
    This Schedule 13G/A is filed jointly by each of the following persons (each a “Reporting Person” and, collectively, as the “Reporting Persons”) pursuant to a joint filing agreement entered into by the Reporting Persons in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), a copy of which was filed with the Schedule 13G filed by the Reporting Persons on February 14, 2018, as Exhibit 1 and is incorporated herein by reference:
     

    1.
    Ever Regal Group Limited, a limited liability company organized under the laws of the British Virgin Islands (“Ever Regal”);
     

    2.
    Fairy Eagle Investments Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fairy Eagle”);
     

    3.
    Rosy Time Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Rosy Time”);
     

    4.
    Lan Huang, a Chinese citizen (“Dr. Huang”); and
     

    5.
    Linqing Jia, a Chinese citizen (“Mr. Jia”).
     
    Dr. Huang is the Co-founder, Chairman and Chief Executive Officer of the Issuer. Dr. Huang’s spouse, Mr. Jia, is the Co-founder of the Issuer.
     
    The principal business address for each of the Reporting Persons is c/o BeyondSpring Inc., 100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, New Jersey 07932.
     
    Item 2(d)
    Title of class of securities:
     
    Ordinary Shares, par value $0.0001 per share
     
    Item 2(e)
    CUSIP Number:
     
    G10830100
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 8 of 12

    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)
    ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________

    Item 4.
    Ownership:
     
    A.
    Ever Regal
       
     
    Amount beneficially owned: 1,431,686

    Percent of class: 3.67%
       
     
    Number of shares as to which the person has:
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    1,431,686
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    1,431,686


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 9 of 12

    B.
    Fairy Eagle
     
         
     
    Amount beneficially owned: 175,000
    Percent of class: 0.45%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    175,000
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    175,000
         
    C.
    Rosy Time
     
         
     
    Amount beneficially owned: 100,000
     
         
     
    Percent of class: 0.26%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    100,000
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    100,000
         
    D.
    Dr. Huang
     
         
     
    Amount beneficially owned: 10,210,523
     
         
     
    Percent of class: 26.17%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    10,210,523
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    2,875,523
         
    E.
    Mr. Jia
     
         
     
    Amount beneficially owned: 10,210,523
     
         
     
    Percent of class: 26.17%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    10,210,523
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    2,875,523
     
    Dr. Huang is the sole owner of Ever Regal and, as such, has the ability to direct the management of the business of Ever Regal, including the power to direct decisions regarding the vote and disposition of securities held by Ever Regal; therefore, Dr. Huang may be deemed to have indirect beneficial ownership of the Ordinary Shares directly owned by Ever Regal. Dr. Huang is also the sole trustee of the Lan Huang 2021 Grantor Retained Annuity Trust and the Lan Huang 2022 Grantor Retained Annuity Trust, and a member of the board of directors of Sincere Efforts Foundation Inc. (“Sincere Efforts”). Dr. Huang disclaims beneficial ownership of the Ordinary Shares held by Sincere Efforts, and nothing herein shall be construed as an admission that Dr. Huang is the beneficial owner of such Ordinary Shares.


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 10 of 12
     
    Mr. Jia is the sole owner of each of Fairy Eagle and Rosy Time and, as such, has the ability to direct the management of the business of each of Fairy Eagle and Rosy Time, including the power to direct decisions regarding the vote and disposition of securities held by each of Fairy Eagle and Rosy Time; therefore, Mr. Jia may be deemed to have indirect beneficial ownership of the Ordinary Shares directly owned by each of Fairy Eagle and Rosy Time.
     
    On May 9, 2023, (i) Ever Regal transferred to three irrevocable trusts (the “Trusts”) for the benefit of Dr. Huang’s children an aggregate of 1,800,000 Ordinary Shares as a gift, and (ii) Fairy Eagle and Rosy Time transferred to certain unaffiliated third-parties (the “Transferees”) 4,445,000 Ordinary Shares and 1,090,000 Ordinary Shares, respectively. As a result of the forgoing transactions, each of Ever Regal, Fairy Eagle and Rosy Time ceased to be deemed the beneficial owner of more than 5% of the outstanding Ordinary Shares of the Issuer.
     
    The trustee of the Trusts granted Dr. Huang voting power over the Ordinary Shares described above, and the Transferees granted Mr. Jia proxy to vote their Ordinary Shares.
     
    The percentages used in this Schedule 13G/A are calculated based upon the Issuer’s 39,015,476 issued and outstanding Ordinary Shares as of June 30, 2023, as reported by the Issuer in its Form 6-K filed with the U.S. Securities and Exchange Commission on February 2, 2024.
     
    Pursuant to Rule 13d-4 of the Exchange Act, the Reporting Persons declare that filing this Schedule 13G/A shall not be construed as an admission that any such person is, for the purposes of Section 13(d) and/or Section 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Schedule 13G/A except to the extent of such person’s pecuniary interest in the Ordinary Shares, and, except to the extent of its, her or his pecuniary interest, such beneficial ownership is expressly disclaimed by each Reporting Person.
     
    Item 5.
    Ownership of 5 Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐
     
    Item 6.
    Ownership of More than 5 Percent on Behalf of Another Person.
     
    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.
     
    Item 10.
    Certifications.
     
    Not applicable.
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 11 of 12
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Date: February 14, 2024
         
     
    EVER REGAL GROUP LIMITED
         
     
    By:
    /s/ Lan Huang
     
     
    Name:
    Lan Huang
     
    Title:
    Director
         
     
    FAIRY EAGLE INVESTMENTS LIMITED
         
     
    By:
    /s/ Linqing Jia
     
     
    Name:
    Linqing Jia
     
    Title:
    Director
         
     
    ROSY TIME HOLDINGS LIMITED
         
     
    By:
    /s/ Linqing Jia
     
     
    Name:
    Linqing Jia
     
    Title:
    Director
         
     
    /s/ Lan Huang
     
     
    Lan Huang
         
     
    /s/ Linqing Jia
     
     
    Linqing Jia
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 12 of 12

    EXHIBIT INDEX

    Exhibit  1
    Joint Filing Agreement, dated as of February 14, 2018, by and among Ever Regal Group Limited, Fairy Eagle Investments Limited, Rosy Time Holdings Limited, Lan Huang and Linqing Jia, as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated herein by reference to Exhibit 1 of the Schedule 13G filed by the Reporting Persons on February 14, 2018).



    Get the next $BYSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

      Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2

      6/3/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

      FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. ​​Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli

      5/28/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

      Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7

      5/12/25 4:30:44 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care